临床药师对中重度特应性皮炎患者实施标准化药物治疗管理服务的效果评价

注册号:

Registration number:

ChiCTR2300068720 

最近更新日期:

Date of Last Refreshed on:

2023-07-22 20:28:18 

注册时间:

Date of Registration:

2023-02-28 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

临床药师对中重度特应性皮炎患者实施标准化药物治疗管理服务的效果评价

Public title:

Evaluation of clinical pharmacists implementing standardized drug therapy management services for patients with moderate to severe atopic dermatitis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

临床药师对中重度特应性皮炎患者实施标准化药物治疗管理服务的效果评价

Scientific title:

Evaluation of clinical pharmacists implementing standardized drug therapy management services for patients with moderate to severe atopic dermatitis

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

信如娟 

研究负责人:

朱全刚 

Applicant:

Xin Rujuan 

Study leader:

Zhu Quangang 

申请注册联系人电话:

Applicant telephone:

+86 189 3983 9316

研究负责人电话:

Study leader's
telephone:

+86 180 1733 6652

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

xinrujuan1112@126.com

研究负责人电子邮件:

Study leader's E-mail:

qgzhu@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市静安区保德路1278号

研究负责人通讯地址:

上海市静安区保德路1278号

Applicant address:

1278 Baode Road, Jing 'an District, Shanghai

Study leader's address:

1278 Baode Road, Jing 'an District, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海市皮肤病医院

Applicant's institution:

shanghai skin disease hospital

研究负责人所在单位:

上海市皮肤病医院

Affiliation of the Leader:

shanghai skin disease hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2022-28(科)

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海市皮肤病医院临床试验伦理委员会

Name of the ethic committee:

Shanghai Dermatology Hospital Clinical Trial Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2022-09-16 00:00:00

伦理委员会联系人:

刘硕

Contact Name of the ethic committee:

liushuo

伦理委员会联系地址:

上海市静安区保德路1278号

Contact Address of the ethic committee:

1278 Baode Road, Jing 'an District, Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 21 36803156

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海市皮肤病医院

Primary sponsor:

shanghai skin disease hospital

研究实施负责(组长)单位地址:

上海市静安区保德路1278号

Primary sponsor's address:

1278 Baode Road, Jing 'an District, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市皮肤病医院

具体地址:

上海市静安区保德路1278号

Institution
hospital:

shanghai skin disease hospital

Address:

1278 Baode Road, Jing 'an District, Shanghai

经费或物资来源:

中关村助帮医疗健康科技创新中心

Source(s) of funding:

Zhongguancun Help Bang Medical health Technology Innovation Center

研究疾病:

特应性皮炎  

Target disease:

atopic dermatitis

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

评价临床药师按照既定的《药学服务标准与路径》,对中重度AD成年患者实施标准化MTM服务对相关治疗有效性的影响。  

Objectives of Study:

To evaluate the effect of clinical pharmacists implementing standardized MTM services for adult patients with moderate to severe AD in accordance with established Standards and Pathways for Pharmaceutical Care on the effectiveness of relevant treatment.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.入组前28天,受试者参加了其他临床试验项目; 2.处于放化疗、靶向治疗、免疫治疗、细胞治疗期间的恶性肿瘤或血液病患者; 3.计划在研究期间进行重大手术的患者; 4.伴有不稳定精神疾病、酗酒、吸毒或药物滥用等情况的受试者。

Exclusion criteria:

1. 28 days before enrollment, the subjects participated in other clinical trial projects; 2. Patients with malignant tumors or hematological diseases who are undergoing radiotherapy, chemotherapy, Targeted therapy, immunotherapy, and cell therapy; 3. Patients planning to undergo major surgeries during the study period; 4. Subjects with unstable mental illness, alcoholism, drug abuse, or other conditions.

研究实施时间:

Study execute time:

From 2023-02-02 00:00:00 To 2024-02-02 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-02-28 00:00:00 To 2024-02-28 00:00:00

干预措施:

Interventions:

组别:

干预组

样本量:

292

Group:

Intervention group

Sample size:

干预措施:

接受为期12周的,由临床药师主导的标准化MTM服务

干预措施代码:

Intervention:

Receive 12 weeks of standardized MTM services led by clinical pharmacists

Intervention code:

组别:

对照组

样本量:

146

Group:

control

Sample size:

干预措施:

干预措施代码:

Intervention:

no

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

shanghai

City:

单位(医院):

上海市皮肤病医院 

单位级别:

三级 

Institution
hospital:

shanghai skin disease hospital

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海长征医院 

单位级别:

三甲 

Institution
hospital:

shanghai changzheng hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京天坛医院 

单位级别:

三甲 

Institution
hospital:

Beijing Tiantan Hospital Affiliated to Capital Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京大学第三医院 

单位级别:

三甲 

Institution
hospital:

Peking University Third Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京友谊医院 

单位级别:

三甲 

Institution
hospital:

Beijing Friendship Hospital, Capital Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京潞河医院 

单位级别:

三甲 

Institution
hospital:

Beijing Luhe Hospital Affiliated to Capital Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

杭州市第三人民医院 

单位级别:

三级 

Institution
hospital:

Hangzhou Third People's Hospital

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

中国医学科学院皮肤病医院 

单位级别:

三级 

Institution
hospital:

Hospital of Dermatology, Chinese Academy of Medical Sciences

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

苏州 

市(区县):

 

Country:

China

Province:

Suzhou

City:

单位(医院):

苏州大学附属第一医院 

单位级别:

三甲 

Institution
hospital:

The First Affiliated Hospital of Soochow University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖北 

市(区县):

 

Country:

China

Province:

Hubei

City:

单位(医院):

武汉市第一医院 

单位级别:

三级 

Institution
hospital:

Wuhan First Hospita

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

辽宁 

市(区县):

 

Country:

China

Province:

Liaoning

City:

单位(医院):

大连医科大学附属第一医院 

单位级别:

三级 

Institution
hospital:

The First Affiliated Hospital of Dalian Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

新疆 

市(区县):

 

Country:

China

Province:

Xinjiang

City:

单位(医院):

新疆自治区人民医院 

单位级别:

三级 

Institution
hospital:

Xinjiang Autonomous Region People's Hospital

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

湖南 

市(区县):

 

Country:

China

Province:

Hunan

City:

单位(医院):

中南大学湘雅医院 

单位级别:

三甲 

Institution
hospital:

Xiangya Hospital, Central South University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

浙江大学医学院附属第二医院 

单位级别:

三甲 

Institution
hospital:

The Second Affiliated Hospital of Zhejiang University School of Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

中山大学附属第一医院 

单位级别:

三甲 

Institution
hospital:

The First Affiliated Hospital of Sun Yat-sen University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

辽宁 

市(区县):

 

Country:

China

Province:

Liaoning

City:

单位(医院):

锦州医科大学附属第一医院 

单位级别:

三甲 

Institution
hospital:

The First Affiliated Hospital of Jinzhou Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

辽宁 

市(区县):

 

Country:

China

Province:

Liaoning

City:

单位(医院):

大连医科大学附属第二医院 

单位级别:

三甲 

Institution
hospital:

The Second Affiliated Hospital of Dalian Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

安徽 

市(区县):

 

Country:

China

Province:

Anhui

City:

单位(医院):

安徽医科大学第一附属医院 

单位级别:

三甲 

Institution
hospital:

The First Affiliated Hospital of Anhui Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市浦东新区人民医院 

单位级别:

三乙 

Institution
hospital:

Shanghai Pudong New Area People's Hospital

Level of the institution:

Tertiary B

国家:

中国

省(直辖市):

辽宁 

市(区县):

 

Country:

China

Province:

Liaoning

City:

单位(医院):

北部战区总医院 

单位级别:

三甲 

Institution
hospital:

The Northern Theater Command General Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

特应性皮炎评分严重程度分级方法

指标类型:

主要指标

Outcome:

Grading method of atopic dermatitis score severity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

湿疹面积及严重程度指数

指标类型:

次要指标

Outcome:

Eczema area and severity index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

研究期间不良事件发生率;

指标类型:

次要指标

Outcome:

Incidence of adverse events during the study period

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

研究期间治疗依从性(实际用药量/应使用药量)

指标类型:

次要指标

Outcome:

Treatment compliance during the study (actual dosage/dosage to be used)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

研究期间全因住院率

指标类型:

次要指标

Outcome:

All-cause hospitalization rate during the study period

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用分层随机,分层因素为AD分级(3级或4级),通过主中心预制随机分配表实现各中心随机分组。随机分配表应有独立于研究者(临床药师)的统计师掌握,并在整个研究过程中保密。

Randomization Procedure (please state who generates the random number sequence and by what method):

Hierarchical randomization is adopted. The hierarchical factor is AD hierarchical (level 3 or level 4). The prefabricated random allocation table of the main center is used to implement random grouping of the centers. The random assignment table should be held by a statistician independent of the investigator (

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

no

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Electronic Data Capture, EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-02-28 09:39:56